Insider Trading Alert - FRX, CREE, IBKR And DIS Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Friday, Jan. 24, 2014, 63 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $199.71 to $33,314,419.42.

Highlighted Stocks Traded by Insiders:

Forest Laboratories (FRX) - FREE Research Report

Solomon Howard who is Director at Forest Laboratories sold 250,000 shares at $67.13 on Jan. 24, 2014. Following this transaction, the Director owned 714,881 shares meaning that the stake was reduced by 25.91% with the 250,000-share transaction.

The shares most recently traded at $65.28, down $1.85, or 2.83% since the insider transaction. Historical insider transactions for Forest Laboratories go as follows:

  • 12-Week # shares sold: 1,104
  • 24-Week # shares sold: 13,104

The average volume for Forest Laboratories has been 2.1 million shares per day over the past 30 days. Forest Laboratories has a market cap of $18.2 billion and is part of the health care sector and drugs industry. Shares are up 8.2% year-to-date as of the close of trading on Friday.

Forest Laboratories, Inc. develops, manufactures, and sells branded forms of ethical drug products in the United States and Europe. The company has a P/E ratio of 118.4. Currently there are 11 analysts that rate Forest Laboratories a buy, no analysts rate it a sell, and 9 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on FRX - FREE

TheStreet Quant Ratings rates Forest Laboratories as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, compelling growth in net income, solid stock price performance, impressive record of earnings per share growth and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Forest Laboratories Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Cramer: There Are Some Bargains Out There

Cramer: There Are Some Bargains Out There

Teva, Actavis, Other Generic Drugmakers May Be on Acquisition Trail

Jim Cramer -- Deal Activity in Specialty Pharma Reaches a Frenzied Pace

Why Endo International Can Deliver Solid Rewards With Minimal Risk

3 Stocks Driving The Health Care Sector Higher